Background: The prescribing of psychoactive drugs is increasing progressively in western countries. The new psychiatric care modalities, in contact with the primary care centres and closer to the population, might be determining this increase in a major way.
Methods: Official data of prescription were collected from the Public Primary Care Department of Pharmacy, to monitor the use of antidepressants during a five year period in a rural health area (140,359 inhabitants). Daily defined dosage (DDD) was used as the measuring unit.
Results and conclusions: The total use of antidepressants increased progressively during the period studied from 10.47 DDD/1000 inhabitants/day in 1995 to 18.50 in 1999 (an increase of 77.08%). The majority of this increase is explained by the greater use of SSRIs for which prescribing multiplied by 2.5. It is significant that the figure for the use of tricyclics has not fallen parallel to the increase of SSRIs. General practitioners might be losing their fear of diagnosing and treating mood disorders. Probably a pool of patients is included who were not receiving the correct treatment a few years ago, but to what level are we going to lower the symptomatic threshold for prescribing antidepressants?
Get full access to this article
View all access options for this article.
References
1.
AMERICAN PSYCHIATRIC ASSOCIATION (2000) Pros and Cons of Prozac and its relatives. American Journal of Psychiatry, Editorial, 3, 323-324.
2.
ALAMO, C., LOPEZ-MUÑOZ, F. & CUENCA, E. (1996) Algunos aspectos éticos en la prescripción de psicofármacos. Archivos de Neurobiología, 59, 79-89.
3.
BLAZER, D.G. , KESSLER, R.C., McGONAGLE, K.A. et al. (1994) The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. American Journal of Psychiatry, 151, 979-986.
4.
D'MELLO, D.A. , FINKBEINER, D.S. & KOCHER, K.N. (1995) The cost of antidepressant overdose. General Hospital Psychiatry, 17, 454-455.
5.
DONOGHUE, J. (2000) Antidepressant use patterns in clinical practices: comparisons among tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica, 403, 57-61.
6.
GARCIA, R. (1995) Introducción a la metodología de los estudios de utilización de medicamentos. In: Matos, L. (ed.) Farmacoepidemiología. Santiago de Compostela, Xunta de Galicia, pp. 191-204.
7.
ISACSSON, G. , BOETHIUS, G., HENRIKSSON, S. et al. (1999) Selective serotonin reuptake inhibitors have broadened the utilization of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database. Journal of Affective Disorders, 53, 15-22.
8.
LAPIERRE, Y. , BENTKOVER, J., SCHAINBAUM, S. et al. (1995) Direct cost of depression: analysis of treatment costs of paroxetine vs imipramine in Canada. Canadian Journal of Psychiatry, 40, 370-377.
9.
LAWRENSON, R.A. , TYRER, F., NEWSON, R.B. et al. (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. Journal of Affective Disorders, 59, 149-157.
10.
MONTGOMERY, S.A. & KASPER, S. (1995) Comparison of compliance between Serotonin Reuptake Inhibitors and Tryciclyc antidepressants: a meta-analysis. International Clinical Psychopharmacology, 9, 33-40.
11.
MYERS, J.K. , WEISSMAN, M.M., TISCHLER, G.L. et al. (1984) Six-month prevalence of psychiatric disorders in three communities. Archives of General Psychiatry, 41, 949-958.
12.
RISPAU-FALGAS, A., SOLER-VILA, M., GARCIA-BAYO, I. et al. (1998) Factores de riesgo asociados al consumo de antidepresivos. Atención Primaria, 22, 440-443.
13.
ROBINS, L. , HELZER, J.E., CROUGHAN, J. et al. (1981) National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics and validity. Archives of General Psychiatry, 38, 381-389.
14.
ROBINS, L. , WING, J., WITTCHEN, H.U. et al. (1988) The Composite International Diagnostic Interview: an epidemiological instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Archives of General Psychiatry, 45, 1069-1077.
15.
SAKLAD, S.R. (1995) Pharmacoeconomic issues in the treatment of depression. Pharmacotherapy, 15, 76-83.
16.
SERVICIO ANDALUZ DE SALUD (1999) Datos oficiales de la Dirección General de Farmacia. Sevilla: Junta de Andalucía.
17.
WORLD HEALTH ORGANIZATION COLLABORATING CENTER FOR DRUG STATISTICS METHODOLOGY (1992) Tryciclyc antidepressants Index including DDDs for plain substances. Oslo: WHO CCDSM.
